Crescent Biopharma
CBIO
78 hedge funds and large institutions have $110M invested in Crescent Biopharma in 2021 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 26 increasing their positions, 25 reducing their positions, and 19 closing their positions.
4% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 25
0.1% less ownership
Funds ownership: 0.81% → 0.71% (-0.1%)
12% less funds holding
Funds holding: 89 → 78 (-11)
24% less capital invested
Capital invested by funds: $145M → $110M (-$35.1M)
28% less call options, than puts
Call options by funds: $594K | Put options by funds: $826K
58% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.99M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
+$2.39M |
| 3 |
SCM
Sio Capital Management
New York
|
+$1.27M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$760K |
| 5 |
BlackRock
New York
|
+$742K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$8.27M |
| 2 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$3.38M |
| 3 |
CCM
CAAS Capital Management
New York
|
-$1.88M |
| 4 |
Morgan Stanley
New York
|
-$1.24M |
| 5 |
Millennium Management
New York
|
-$619K |
CBIO Hedge Fund Activity: Q1 2021 in Review
78 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q1 2021, worth a combined $110M — down 24% from $145M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of CBIO and 8 opened new positions — a net loss of 11 holders — while 25 trimmed existing stakes and 26 added.
The largest buyer was Acadian Asset Management, adding an estimated $2.99M. The largest seller was Camber Capital Management, exiting entirely with an estimated $8.27M sold.
- 78 institutional investors held Crescent Biopharma (CBIO) as of Q1 2021, down from 89 in Q4 2020.
- Funds reported $110M of Crescent Biopharma stock for Q1 2021, down 24% quarter-over-quarter.
- 8 funds opened new Crescent Biopharma positions in Q1 2021 and 19 closed out, a net change of -11 holders.
- The largest Crescent Biopharma buyer in Q1 2021 was Acadian Asset Management, an estimated $2.99M added.
- The largest Crescent Biopharma seller in Q1 2021 was Camber Capital Management, an estimated $8.27M sold.
Based on aggregated 13F filings for Q1 2021.